Tag: Biosimilars
“Popularity of biosimilars will continue to rise, attracting more interest &...
Ravikrishna Chebolu, General Manager, India, West Pharmaceutical Services, Inc. talks about company’s product offerings, latest activities, market trends, unique strategies and future outlook.
Biocon Biologics partners Sandoz Australia for sale of biosimilars, Trastuzumab &...
The agreement is effective from January 1, 2024 and commercialization commenced on February 1, 2024
Biocon clocks Rs 4,519 crore revenue in Q3 of FY24, earns...
The company revenue in biosimilars went up by 65%; research services up by 9%; EBITDA stood at Rs 1,492 Crore, up 106%; Net Profit at Rs 660 Crore
Biocon Biologics concludes integration of acquired biosimilars business in 120 countries
Over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris.
Biocon Biologics successfully completes integration of Viatris’ biosimilar business in 31...
In Europe, Biocon Biologics portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept
Biocon Biologics announces divestment of two non-core branded formulations business units
The move is in line with the company’s strategy to sharpen focus on core therapy areas as a fully integrated biosimilars company
Biocon Biologics receives European Commission approval for YESAFILI biosimilar Aflibercept
Aflibercept had EU brand sales of approximately $1.8B for the 12 months ending December 31, 2022, according to IQVIA
Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
Continuing to expand its global footprint, the company has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023
India’s biosimilars industry staring at plethora of opportunities
Between now and 2030, biologic products worth US $170 billion will lose patent protection globally, writes Dr Cyrus Karkaria, President – Biotechnology, Lupin Limited
Inflation law drives biologic drugs to outpace small molecules in venture...
According to GlobalData’s Pharma Intelligence Center Deals database, the US biotechs saw 48% or $1.1 billion more in innovator drug venture financing, reaching a total deal value of $3.2 billion in 2023